- Home
- ZLAB vs CNS Comparison
ZLAB vs CNS Comparison
Compare ZLAB & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- CNS
- Stock Information
- Founded
- ZLAB 2013
- CNS 1986
- Country
- ZLAB China
- CNS United States
- Employees
- ZLAB N/A
- CNS N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- CNS Investment Managers
- Sector
- ZLAB Health Care
- CNS Finance
- Exchange
- ZLAB Nasdaq
- CNS Nasdaq
- Market Cap
- ZLAB 3.6B
- CNS 4.0B
- IPO Year
- ZLAB 2017
- CNS 2004
- Fundamental
- Price
- ZLAB $33.57
- CNS $72.57
- Analyst Decision
- ZLAB Buy
- CNS Hold
- Analyst Count
- ZLAB 5
- CNS 3
- Target Price
- ZLAB $54.28
- CNS $82.33
- AVG Volume (30 Days)
- ZLAB 718.8K
- CNS 216.4K
- Earning Date
- ZLAB 08-07-2025
- CNS 07-17-2025
- Dividend Yield
- ZLAB N/A
- CNS 3.42%
- EPS Growth
- ZLAB N/A
- CNS 23.33
- EPS
- ZLAB N/A
- CNS 3.15
- Revenue
- ZLAB $418,326,000.00
- CNS $543,579,000.00
- Revenue This Year
- ZLAB $44.07
- CNS $6.76
- Revenue Next Year
- ZLAB $49.13
- CNS $10.52
- P/E Ratio
- ZLAB N/A
- CNS $23.06
- Revenue Growth
- ZLAB 43.72
- CNS 11.54
- 52 Week Low
- ZLAB $16.01
- CNS $68.99
- 52 Week High
- ZLAB $44.34
- CNS $110.67
- Technical
- Relative Strength Index (RSI)
- ZLAB 44.39
- CNS 37.86
- Support Level
- ZLAB $32.31
- CNS $73.94
- Resistance Level
- ZLAB $36.53
- CNS $77.41
- Average True Range (ATR)
- ZLAB 1.11
- CNS 2.46
- MACD
- ZLAB -0.20
- CNS -0.32
- Stochastic Oscillator
- ZLAB 27.12
- CNS 5.38
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.